Home
Biography
Membership
Publications
Book Chapters
Congress Presentations
Discoveries
Opinion Paper
Links
Contact
  
 
1)        E. Kovacs, W. Weber and HJ. Müller.  
Age-related variations in the DNA-repair synthesis after UV-C irradiation in unstimulated lymphocytes of healthy blood donors. Mutation Research 131, 231-237 (1984).

2)HJ. Müller, N. Bürki, A. Gencik, A. Gencikova, E. Kovacs, M. Roth, N. 
Trächslin, B. Voegtli, W.
Weber.
Familiäre Tumorkrankheiten. Erste Ergebnisse einer Erhebung über ihr Vorkommen in Basel. Sozial- und Präventivmedizin 30, 28-32 (1985).

3)E. Kovacs, D. Stucki, W. Weber and HJ. Müller
Impaired DNA-repair synthesis in lymphocytes of breast cancer patients. Eur J Cancer Clin Oncol 22, 863-869 (1986).

4)E. Kovacs and A. Almendral.
Reduced DNA repair synthesis in healthy women having first degree relatives with breast cancer. Eur J Cancer Clin Oncol 23, 1051-1057 (1987).

5)E. Kovacs, C. Nissen, B. Speck and E. Signer.
Repair of UV-induced DNA damage in aplastic anaemia: Changes after treatment with antilymphocyte globulin (ALG). Eur J Haematol 40,430-436 (1988).

6)E. Kovacs and H. Langemann.
Defective DNA repair in a large family having a high occurrence of cancer. Oncology
45, 444-447 (1988).

7)E. Kovacs and H. Langemann.
Investigation of the repair of single-strand breaks in human DNA using alkaline gel electrophoresis. Radiation Research 124, 137-140 (1990).

8)E. Kovacs and H. Langemann.
Differences in the kinetics of DNA repair in cancer patients and healthy controls. Oncology 48, 312-316 (1991).

9)E. Kovacs, T. Hajto and K. Hostanska.
Improvement of DNA repair in lymphocytes of breast cancer patients treated with Viscum album extract (Iscador). Eur J Cancer 27, 1672-1676 (1991).   

10)Eva Kovacs, H. langemann and H. Ludwig.
Do chemo-and radiotherapy affect the DNA repair ability of lymphocytes? Arch Gynecol Obstet 251, 121-126 (1992).

11)    E. Kovacs, M. Meichsner-Frauli and H. Ludwig.
lnterleukin-2 receptor positive cells in human decidua during the first trimester of pregnancy and their association with macrophages. Arch Gynecol Obstet 251, 93-100 (1992).

12)E. Kovacs
Serum levels of IL-12 and the production of IFN-gamma, IL-2 and IL-4 by peripheral blood mononuclear (PBMC) in cancer patients treated with Viscum   
album extract. Biomedicine & Pharmacotherapy 54, 305-310 (2000).

13)E. Kovacs
The serum levels of IL-12 and IL-16 in cancer patients. Relation to the 
tumour stage and previous therapy. Biomedicine & Pharmacotherapy 55, 111-116 (2001).

14)E. Kovacs
Investigation of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and 
soluble gp130 (sgp130) in sera of cancer patients. Biomedicine & Pharmacotherapy
55, 391-396 (2001).

15)E. Kovacs
Zur Rolle der DNA-Reparatur In der Karzinogenese und der Effekt von 
Iscador auf die DNA-Reparaturfähigkeit bei Krebspatienten. Mistelteinn 2, 34-43 (2001).

16)JJ. Kuehn and E. Kovacs.
Lectin compared to mistletoe use: experimental therapy form with preclinical verified risk potential. Dtsch Med Wochenschr 127, 2637-2638 (2002).

17)E. Kovacs
The in vitro effect of Viscum album extract on DNA repair of peripheral 
blood mononuclear cells (PBMC) in cancer patients. Phytotherapy Research
16, 143-147 (2002).

18)E. Kovacs and JJ Kuehn.
Measurements of IL-6, soluble IL-6 receptor and soluble gp130 in sera of B-cell lymphoma patients. Does Viscum album treatment affect these parameters? Biomedicine & Pharmacotherapy 56, 152-158 (2002).

19)E. Kovacs
How does interleukin-6 affect the membrane expressions of interleukin-6 receptor and gp130 and the proliferation of the human myeloma cell line OPM-2? Biomedicine & Pharmacotherapy 57, 489-494 (2003).

20)E. Kovacs
Effects of Viscum album (VA) therapy in cancer patients. Relation 
with interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130). 
The Journal of Alternative and Complementary Medicine 10, 241-246 (2004). 

21)E. Kovacs
The serum levels of soluble intercellular adhesion molecule-1 (sICAM-1) and
soluble gp130 (sgp130) in different tumour stages. Correlation between the two parameters in progression of malignancy. Biomedicine & Pharmacotherapy 59, 498-500 (2005).

22)E. Kovacs, S. Link and U. Toffol-Schmidt.
Cytostatic and cytocidal effects of mistletoe (Viscum album L.) Quercus extract Iscador. Drug Research 56, 467-473 (2006).

23)E. Kovacs
Multiple myeloma and B cell lymphoma. Investigation of IL-6, IL-6 receptor antagonist (IL-6RA) and gp130 antagonist (gp130A) using various parameters in an in vitro model. The Scientific World Journal 6, 888-898 (2006).

24)E. Kovacs, S. Link, U. Toffol-Schmidt.
Comparison of Viscum album QuFrF extract with Vincristine in an in vitro model of human B cell lymphoma WSU-1. Drug Research 58, 592-597 (2008).

25)E. Kovacs
Investigation of the proliferation, apoptosis/necrosis and cell cycle phases in several human multiple myeloma cell lines. Comparison of Viscum album QuFrF extract with Vincristine in an in vitro model. The Scientific World Journal 10, 311-320 (2010).

26)E. Kovacs
Interleukin-6 leads to Interleukin-10 production in several human multiple myeloma cell lines. Does Interleukin-10 enhance the proliferation of these cells?
Leukemia Research 34, 912-916 (2010).

27)E. Kovacs-Benke
Tumor necrosis factor-alpha (TNF-alpha) production in human multiple myeloma cells is influenced only by Interleukin-6. (Manuscript in preparation).

28)E. Kovacs-Benke
Investigation of the Proliferation, Apoptosis/Necrosis, and Cell Cycle Phases in Several Human Multiple Myeloma Cell Lines. Comparison of Viscum album QuFrF Extract with Vincristine in an In Vitro Model.The Scientific World Journal 10, 311-20 (2010).

29)E. Kovacs-Benke
The effect of minerals in natural mineral water on the serum-parameters of bone-metabolism. Research Gate, (2014).

30)E. Kovacs-Benke
Additive/Synergistic Effects of Interleukin-6 and Interleukin-10 on the Proliferation of Human Myeloma Cells. International Journal of Hematology Research 1(3), 74-78 (2015).

31)E. Kovacs-Benke
Low/High Proliferation Rate of Human Myeloma Cells, Investigation of Interleukin-6 and Interleukin-6 Receptor Antagonist. International Journal of Hematology Research
2(1)
, 115-119 (2016).

32)E. Kovacs-Benke
Monitoring Disease Status in Multiple Myeloma in View of Proliferation-leading Cytokines. Journal of Hematology & Multiple Myeloma, Volume 2 / Issue 1 / Article 1010 (2017).